admin – Page 3219 – Get News Story

Esports World Cup Foundation Welcomes OBSBOT as Official Camera and Webcam Partner for Esports World Cup 2025

New AI-powered camera technology set to elevate broadcasts and transform creators’ EWC storytelling with unparalleled video quality and innovative features

The Esports World Cup Foundation (EWCF) today announced OBSBOT, as an official camera and webcam partner for the Esports World Cup (EWC) 2025, set to return to Riyadh, Saudi Arabia, this summer. The two-year partnership will integrate OBSBOT’s next-generation AI camera technologies into the EWC’s production capabilities, providing enhanced video quality and immersive experiences for millions of fans around the world. The partnership supports the EWC’s broader strategy to connect Chinese esports with its global ecosystem, strengthening ties with one of the world’s most dynamic gaming markets and bringing the best of China’s innovation to the global esports stage.

The 2025 Esports World Cup will spotlight every player’s journey, showcasing their skill, competitive excellence and relentless pursuit of victory. OBSBOT will support this vision by outfitting player areas, streaming stations, and venue activations with its latest devices, the Tail 2 smart-tracking camera and the Tiny 2 webcam, both designed with esports creators in mind.

“The Esports World Cup is built on innovation, and technology plays a crucial role in creating unforgettable moments for players, Clubs and fans,” said Mohammed Al Nimer, Senior Sales Director, Esports World Cup Foundation. “Our partnership with OBSBOT is at the heart of this vision. Its cutting-edge camera technology demonstrates the power of AI in esports today, capturing the intensity and emotion that defines competition at this level and bringing fans into the moment. We are thrilled to have OBSBOT as our Official Camera and Webcam Partner as we continue raising the bar for esports experiences worldwide.”

OBSBOT offers standout solutions like the Tail 2 and Tiny 2. Tail 2, a 4K PTZR live production camera powered by AI Tracking 2.0, delivers smooth, cinematic shots with minimal manual input and integrates seamlessly with professional broadcasting environments through NDI and other pro-grade outputs. The Tiny 2, the flagship webcam in OBSBOT’s lineup, provides exceptional image quality and unparalleled tracking performance in a compact desktop form. Whether on stage or at the desk, OBSBOT’s technology ensures streamers can stay focused on the game while the camera keeps up.

“We believe that everyone’s story deserves to be seen and shared, and the Esports World Cup provides the perfect platform for us to showcase our vision,” said Liu Bo, CEO & Founder of OBSBOT. “Through our partnership with the Esports World Cup, we are bringing our cutting-edge AI-powered camera technology to millions of gamers and content creators, celebrating the excitement, drama, and triumphs of elite competition on the world’s biggest stage. This collaboration is about more than just capturing moments; it’s about empowering a new generation of storytellers to create, share, and inspire with professional-grade tools that are as dynamic as the esports community itself.”

Returning to Riyadh, Saudi Arabia, from July 7 to August 24, 2025, the Esports World Cup will unite global gaming communities for a celebration of esports culture. With 25 tournaments across 24 games, 2,000 elite players, and 200 Clubs from over 100 countries, the EWC will feature the largest prize pool in esports history, over $70 million. Fans can expect exclusive experiences, from high-stakes competition to live music, anime cafes, retro arcades, cosplay, and more, drawing millions of fans online and in person.

To learn more about EWC, visit esportsworldcup.com and follow Esports World Cup Foundation on LinkedIn.

About The Esports World Cup

The Esports World Cup (EWC) is a premier annual sporting event and global celebration of competitive excellence and esports fandom. The competition features a unique cross-game format that pits the world’s top esports clubs against one another for the largest prize pool in esports history. Returning to Riyadh, Saudi Arabia, in the summer of 2025, the EWC will bring gaming and esports communities together again to crown the next Esports World Cup Club Champion. esportsworldcup.com

About OBSBOT

OBSBOT, a global leader in smart videography technology, is dedicated to connecting people and the imaging industry to the future. Founded in 2016, and headquartered in Shenzhen, we empower live streamers and content creators with cutting-edge AI technology and exceptional image quality. Trusted by a diverse community of users, from individual creators to industry professionals and business partners, we’re committed to revolutionizing visual storytelling and redefining how people connect, create, and share through groundbreaking technology and innovation. obsbot.com

Esports World Cup media contact:

Anna Rozwandowicz

Head of PR

a.rozwandowicz@worldcupfoundation.org

The Story Mob

EWC@thestorymob.com

OBSBOT media contact:

Rain Hu

PR Manager

rain@obsbot.com

Media Contact
Company Name: OBSBOT
Contact Person: Rain Hu
Email: Send Email
Country: China
Website: https://www.obsbot.com/

Hunan Museum Announces Latest Findings on the Mawangdui Han Tomb

As an important connector, innovator, and guardian of cultural identity, Hunan Museum has launched the “Xiangyun · Rebirth” series of activities since May 16, aligning with this year’s International Museum Day theme “The Future of Museums in a Rapidly Changing Society.” Focusing on three dimensions—deepened research, digital revitalization, and innovative communication & services—the Museum aims to release and showcase its recent achievements and future plans to the public, breathing new life into ancient cultural heritage in the new era.

In response to the contemporary proposition of scientific and technological innovation-driven development, Hunan Museum relies on technology to empower cultural heritage research. With the continuous advancement of research on cultural relics unearthed from the Mawangdui Han Tombs, and with the technical support of modern high-definition equipment, breakthrough progress has been made in its research. One such breakthrough involves Chengyun Embroidery (“Cloud-Riding Embroidery”), long misidentified as a “pillow towel.”

Comparative analysis of excavation data and historical records confirmed it as China’s earliest known yinxi (silk cushion), reshaping academic and public understanding. Another discovery emerged through high-resolution scans of the Mawangdui T-shaped Painting on Silk. Researchers identified repainting traces in figures like Dihun (heavenly gate guardians) and the Divine Leopard, offering new insights into Han Dynasty artistic techniques. The third finding is the identification of a double-phoenix motif in the Chengyun Embroidery—a significant addition to Mawangdui embroidery studies—highlighting the aesthetic values and craftsmanship of Han textile art.

Hunan Museum also unveiled outcomes from two digital heritage initiatives: Exploring Yuan Plan 2024 and Digital Han Lifestyle. The former used AI to recreate a Western Han straight-cut, printed, color-painted silk-padded robe, showcasing exquisite detail, historical depth, and dynamic beauty—granting the garment a digital rebirth. Meanwhile, Digital Han Lifestyle offers an immersive exploration of Han clothing, cuisine, dwellings, transportation, and spiritual aesthetics. Visitors can wear Han robes, enjoy traditional banquets, and experience classical music, engaging with Chinese heritage across dimensions.

By unveiling these achievements, Hunan Museum not only affirms its leading role in digital heritage innovation but also opens new windows for the public to engage with Han civilization—fostering the creative transformation and dynamic transmission of Chinese traditional culture in the digital age.

Media Contact
Company Name: Hunan Museum
Contact Person: Jason Zou
Email: Send Email
City: Changsha
Country: China
Website: https://www.hnmuseum.com

The PPLP Fan Efficiency Star Rating Standard is Officially Launched, LianLi Becomes the first to Receive Star Ratings

The PPLP Power Supply Efficiency Star Rating Program is an independent evaluation system for PC power supplies launched by PPLP Lab, designed to provide a more comprehensive and accurate assessment of power supply quality. In addition to power supplies, PPLP has previously announced plans to expand its evaluation scope to include products such as heatsinks, PC cases, and PC fans.

Today, PPLP has undergone an upgrade, with its full name updated from the original PSU Performance Level Plan to the Pro Performance Level Plan. Simultaneously, the DC Axial Fan Efficiency Star Rating Standard, as part of the Pro Performance Level Plan, has officially launched. Leading global PC hardware manufacturer Lian Li has joined this initiative in close collaboration, becoming one of the first partners. Among its product lines, the UNI FAN SL INFINITY and TL WIRELESS series have become the first fans to receive PPLP star ratings, with the TL WIRELESS 120 achieving an A-star rating under the PPLP program.

Compared to the power supply market, the fan market has lower entry barriers, resulting in a more uneven quality landscape—with no widely recognized evaluation standard to measure performance. For most users, understanding a fan’s true quality relies solely on the manufacturer’s advertised specifications, which provide limited insight. Although some high-end brands include more informative P/Q curves on packaging or product pages, most users either overlook them or fail to study them closely. This is largely because P/Q curves typically only depict performance for a single product or two generations from the same brand, lacking intuitive and comprehensive comparisons.

The introduction of PPLP DC Axial Fan Efficiency Star Rating Standard aims to bridge this knowledge gap for consumers. Leveraging newly established testing protocols, rigorous and reliable equipment, a fully controlled testing environment, and the expertise of the PPLP Lab team—which has over a decade of experience in PC hardware testing—this standard provides a clear and effective performance rating. Users can rely on it to choose the right fan for their needs, while manufacturers can use it to accurately classify their product lines.

PPLP Lab will evaluate fan products across multiple dimensions, delivering comprehensive and detailed analysis reports. Key performance metrics include:

• Rotational speed

• Airflow volume

• Effective airflow

• Static pressure

• Noise level

• Power consumption

• Performance efficiency ratio

• Vibration amplitude

Among these, effective airflow (representing genuine performance) and noise level (directly impacting user perception) are given the highest priority.

Effective airflow is measured by testing a fan’s performance in a wind tunnel with three standardized impedance configurations: a chassis mesh front panel, an air cooler tower, and a 27mm-thick radiator. This setup replicates real-world usage scenarios while incorporating weighted factors to reflect a fan’s comprehensive performance.

The core of this standard lies in testing effective airflow under three standardized impedance conditions across 12 noise level tiers. The noise range spans from 27dB(A) to 60dB(A), with each 3dB(A) increment representing a distinct test condition. As the noise level increases, the corresponding quality coefficient decreases, directly impacting the final evaluation score. In other words, this standard evaluates different fan types within a unified noise-efficiency framework, requiring products to not only deliver exceptional low-noise performance but also demonstrate strong upper-end efficiency.

The PPLP DC Axial Fan Efficiency Star Rating Standard provides a comprehensive performance grading system, categorizing fans into five star levels from highest to lowest based on evaluation results: S, A+, A, B+, and B.

PPLP states that evaluation samples can be provided by the submitting party or purchased directly from the market. Each product undergoing evaluation requires at least two samples. If there is a significant performance difference between these two samples, additional new samples must be provided or purchased until the evaluation is completed. Additionally, PPLP Lab registers each participating sample with a unique identifier and stores it securely for at least one year after the evaluation is concluded.

It is reported that another core component of the PPLP Case Cooling Efficiency Star Rating Standard is now ready and will be announced to the public shortly.

Official Website: https://www.pplp.info

Media Contact
Company Name: PPLP
Contact Person: Miss Ru
Email: Send Email
Phone: 020-85510156
City: Guangzhou
Country: China
Website: https://www.pplp.info

SmoothSEO Launches RankReady: First Dual-Engine Content Creation Platform Built for SEO and AI Search Optimization

LONDON, UNITED KINGDOM – May 21, 2025 – SmoothSEO, a technology innovator and SEO company in the digital marketing space, has announced the launch of RankReady, a breakthrough content creation tool designed to optimize digital content for both traditional Search Engine Optimisation (SEO) and emerging AI-driven search technologies.

RankReady - The SEO Content Generation tool for the modern era.

As businesses navigate an evolving search landscape, RankReady addresses a growing challenge: creating content that excels in ranking content on Google today while remaining effective in AI-powered search systems of tomorrow. This dual-focus approach makes RankReady the first platform to integrate SERP-based analysis with AI knowledge pattern recognition in one unified workflow.

“Content strategy needs to evolve alongside the tools interpreting it,” said Benjamin Grimes, CEO and CTO of SmoothSEO. “With RankReady, we’re giving solopreneurs, teams, and agencies the ability to plan and create content that speaks to both algorithms and AI.”

RankReady uses a dual-analysis engine that blends conventional SERP insights with how generative AI systems comprehend context, topics, and sources. Users begin by entering a keyword or topic, and the system generates an optimization blueprint, complete with article length, keyword density, and semantic topic clusters. The platform also includes a smart editor offering real-time feedback and a scoring system that evaluates performance from SEO and AI perspectives.

Key Capabilities of the RankReady Platform Include:

SERP Analysis Module: Identifies trends and benchmarks from top-ranking content.
AI Knowledge Pattern Module: Detects entity relationships and informational structures favored by AI.
Real-Time Content Evaluation Engine: Delivers in-line optimization feedback and semantic coverage suggestions.
Full Optimization Checklist: Covers metadata, structured data, and alt tags with actionable improvement tips.
Export Options: Supports content deployment across multiple CMS platforms.

By integrating the technical precision of SEO with AI readability, RankReady helps content creators align their output with how digital platforms assess and prioritize information. Whether a freelance marketer or part of a large content team, the tool simplifies ranking content on Google and enhances visibility in conversational AI search environments.

Pricing & Availability

RankReady is available immediately with flexible plans starting at $79/month for individual users. Team and enterprise subscriptions are also offered. To learn more or begin an optimized content strategy, visit https://www.smoothseo.co.

About SmoothSEO

SmoothSEO is a UK-based technology company committed to creating next-generation tools for digital marketers. The company’s solutions are designed to bridge the gap between traditional Search Engine Optimisation and the evolving world of AI-powered content discovery. With RankReady, SmoothSEO is redefining what a modern content creation tool can achieve.

SmoothSEO - SEO Tools for the modern era

Media Contact
Company Name: SmoothSEO
Contact Person: Benjamin Grimes
Email: Send Email
Phone: 07707822907
Country: United Kingdom
Website: https://www.smoothseo.co/

SOUEAST Concludes “Lighting Up the Middle East”, Reinforces Regional Commitment

May 21, 2025 – SOUEAST Motor has wrapped up its over-month-long “Lighting Up the Middle East” campaign, illuminating five iconic landmarks with its vibrant brand color, Ease Orange, paying tribute to EASE lifestyle. From Qatar to the UAE, this high-impact activation promoted the brand´s philosophy: “EASE YOUR LIFE.”The campaign generated widespread public attention, drawing the eyes of over 560 million viewers both online and on-site.

A Regional Tour of Light and Innovation

Through a grand light show, the brand philosophy was deeply embedded in the urban contexts of different countries in the form of artistic lighting, showcasing SOUEAST’s understanding and resonance with the “EASE Urban Lifestyle.”

First Stop: Igniting Qatar

On February 17, SOUEAST’s light show kicked off in Qatar. As night fell, the Aspire Tower, Qatar’s tallest building, was illuminated in the brand’s signature “Ease Orange,” resembling a beam of light piercing the night sky, and becoming the most dazzling presence in the city’s nightscape.

(Image 1: SOUEAST “Lighting Up the Aspire Tower”)

Second Stop: Shining on the Skyline in Iraq

On February 20, the “Ease Orange” glow lit up the night sky in Iraq as SOUEAST presented an immersive light show blending technology and art at the Erbil 1 Tower. The entire building became a stage for lighting, with the brand slogan and SUV lineup flashing alternately across its facade, capturing the city’s attention.

(Image 2: SOUEAST “Lighting Up the Erbil 1 Tower”)

Third Stop: Illuminating the Pearl of the Gulf

On February 24, Kuwait City was “lit up” by SOUEAST. At the Kuwait landmark, the Avenues-Kuwait, wrapped in “Ease Orange,” shone like a urban pearl in the night, turning into a vibrant symbol of the city’s pulse in this Gulf nation.

(Image 3: SOUEAST “Lighting Up the Avenues-Kuwait”)

Fourth Stop: Interweaving Light and Shadow in Saudi Arabia

On March 15, SOUEAST brought “Ease Orange” to Boulevard City Times Square, a trendy landmark in Riyadh. Multiple giant digital screens scrolled through animations of the brand and models, transforming the square into a digital art space for “EASE,” perfectly presenting a visual feast where technology and humanity intertwine.

(Image 4: SOUEAST “Lighting Up the Boulevard City Times Square”)

Fifth Stop: Dancing with the Wavesin the UAE

On March 20, SOUEAST’s “Lighting Up the Middle East” campaign reached its final stop, as the night sky over Jumeirah Beach Residence (JBR) in Dubai grew even more radiant with the SOUEAST’s light display. The brand slogan and model projections shimmered on the sea, with lights dancing alongside the waves, creating a unique urban spectacle.

(Image 5: SOUEAST “Lighting Up the Jumeirah Beach Residence”)

Strengthening Brand Presence

The campaign offered a unique glimpse into SOUEAST´s long-term commitment to the region. It showcased a lineup of three SUVs for the market:

S09, a Smart Premium D-class SUV offering fashionable aesthetics, premium interiors, and spacious comfort.
S07, an Urban Intelligent C-class SUV tailored for urban trendy youth.
S06, an Urban Stylish C-class SUV, with hybrid S06 DM version for efficiency and long-range driving.

All models undergo rigorous high-temperature durability testing, ensuring reliable performance in the Middle East´s demanding climate.

(Image 6: SOUEAST SUV Lineup)

Deepening Regional Roots

The campaign also supports SOUEAST´s broader Middle East strategy. With the establishment of its Saudi subsidiary, the company has opened a 12,000 m² spare parts center. In addition, it plans to enter the market of Saudi Arabia, Bahrain, Oman, and Lebanon while establishing 14 new sales outlets, expanding access to products and services, and enhancing customer trust and convenience.

The Journey Continues

With the conclusion of the “Lighting Up the Middle East” campaign, SOUEAST signals a new phase of engagement: one focused on long-term integration through localization, innovation, and brand affinity. Though the lights have dimmed, SOUEAST´s commitment to illuminating the region´s mobility future continues.

(Image 7: SOUEAST Lights Up the Middle East Night)

Media Contact
Company Name: SOUEAST MOTOR
Contact Person: Frida Fu
Email: Send Email
City: Riyadh
Country: Saudi Arabia
Website: https://www.soueast-motor.com/

Common Warts Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Verrica Pharma, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics, KinoPharma Inc

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Common Warts pipeline constitutes 5+ key companies continuously working towards developing 5+ Common Warts treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Common Warts Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Common Warts Market.

The Common Warts Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Common Warts Pipeline Report:

Companies across the globe are diligently working toward developing novel Common Warts treatment therapies with a considerable amount of success over the years.
Common Warts companies working in the treatment market are Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma/ Iwaki Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma Inc., ViroXis Corporation, Maruho Co., Ltd., Veradermics, Inc., Graceway Pharmaceuticals, LLC, MEDA Pharma, LEO Pharma, and others, are developing therapies for the Common Warts treatment

Emerging Common Warts therapies in the different phases of clinical trials are- CANDIN, VP-102, FIT039, A-101, KNP2002, 10% EISO, CLS006, VDMN-21, Resiquimod, Imiquimod, Picato, and others are expected to have a significant impact on the Common Warts market in the coming years.
In May 2025, Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced progress in its late-stage development pipeline, highlighted by the completion of an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for VP-315, the company’s investigational treatment for basal cell carcinoma. Additionally, Verrica is making strides toward launching a global Phase 3 clinical program for VP-102/YCANTH, its treatment candidate for common warts, in collaboration with its partner, Torii Pharmaceutical.
In February 2025, Nielsen BioSciences, Inc., a privately held biopharmaceutical company headquartered in San Diego, announced the successful enrollment of the final participant in its Phase 3 clinical trial, CFW-3A. This randomized, double-blind, placebo-controlled study is evaluating the safety and efficacy of CANDIN® (Candida albicans Skin Test Antigen for Cellular Hypersensitivity) for treating common warts (Verruca vulgaris) in both adolescents and adults. It’s important to note that CANDIN is not yet approved for this indication.
In December 2024, Veradermics was a late-stage clinical biopharmaceutical company specializing in aesthetics and dermatology, dedicated to developing innovative therapies for common skin disorders. Its leading product, VDPHL01, is a non-hormonal oral treatment currently being tested for androgenetic alopecia (AGA) and pattern hair loss (PHL) in both male and female patients. Additionally, the company’s pipeline features treatments targeting widespread dermatological conditions like warts and molluscum contagiosum.
In August 2024, Verrica Pharmaceuticals reported encouraging new findings from its Phase 2 trial of the oncolytic peptide VP-315 for basal cell carcinoma treatment. With positive safety and efficacy outcomes, the company sees VP-315 as a potential first-line therapy for this cancer type. Comprehensive results will be shared at an upcoming KOL event. Furthermore, Verrica has revised its agreement with Torii Pharmaceutical Inc. Ltd., supporting the progression of YCANTH into Phase 3 trials for common warts. Addressing a significant unmet need in dermatology, YCANTH has the potential to become a new standard of care, as no FDA-approved treatments currently exist for common warts.
In May 2024, Verrica Pharmaceuticals announced an update to its collaboration and licensing agreement with Torii Pharmaceutical Co. Ltd. to jointly fund the global Phase 3 clinical trial for YCANTH® targeting common warts. According to the revised terms, both companies will equally share the trial expenses, with Torii covering Verrica’s share by offsetting future payments related to regulatory milestones and sales of YCANTH for molluscum contagiosum and common warts in Japan. Furthermore, Torii will make an $8.0 million milestone payment to Verrica upon dosing the first patient in Japan, with the Phase 3 trial expected to commence in the first half of 2025.

Common Warts Overview

Common warts are small, noncancerous skin growths caused by the human papillomavirus (HPV). They typically appear on the hands, fingers, or other areas prone to minor cuts and abrasions. Common warts have a rough, grainy texture and are often flesh-colored, with tiny black dots (clotted blood vessels) on the surface.

Get a Free Sample PDF Report to know more about Common Warts Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/common-warts-pipeline-insight

Emerging Common Warts Drugs Under Different Phases of Clinical Development Include:

CANDIN: Nielsen BioSciences/Maruho
VP-102: Verrica Pharmaceutical
FIT039: Kino Pharma/ Iwaki Pharmaceutical
A-101: Aclaris Therapeutics, Inc.
KNP2002: KinoPharma Inc.
10% EISO: ViroXis Corporation
CLS006: Maruho Co., Ltd.
VDMN-21: Veradermics, Inc.
Resiquimod: Graceway Pharmaceuticals, LLC
Imiquimod: MEDA Pharma
Picato: LEO Pharma

Common Warts Route of Administration

Common Warts pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Common Warts Molecule Type

Common Warts Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Common Warts Pipeline Therapeutics Assessment

Common Warts Assessment by Product Type
Common Warts By Stage and Product Type
Common Warts Assessment by Route of Administration
Common Warts By Stage and Route of Administration
Common Warts Assessment by Molecule Type
Common Warts by Stage and Molecule Type

DelveInsight’s Common Warts Report covers around 5+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Common Warts product details are provided in the report. Download the Common Warts pipeline report to learn more about the emerging Common Warts therapies

Some of the key companies in the Common Warts Therapeutics Market include:

Key companies developing therapies for Common Warts are – Nielsen BioSciences, Veloce BioPharma, Verrica Pharmaceutical, Maruho Co., Aclaris Therapeutics, and others.

Common Warts Pipeline Analysis:

The Common Warts pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Common Warts with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Common Warts Treatment.
Common Warts key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Common Warts Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Common Warts market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Common Warts drugs and therapies

Common Warts Pipeline Market Strengths

The rising prevalence of warts is encourages companies in the life sciences industry to focus on research and development of new drugs for warts treatment. There is a continuous need for new, innovative therapeutic approaches for better treatment outcomes.
An increase in emerging new drugs for the treatment of warts will lead to better patient outcomes in the coming years.

Common Warts Pipeline Market Opportunities

Recent studies have shown the safe and efficacious role of Zinc supplementation in warts clearance, particularly for patients who have not responded to treatments previously.
Secondary research on the warts therapeutics market suggests that the market is saturated with limited drug opportunities providing the key Pharma players a successful domain to work with utmost robustness

Scope of Common Warts Pipeline Drug Insight

Coverage: Global
Key Common Warts Companies: Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma/ Iwaki Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma Inc., ViroXis Corporation, Maruho Co., Ltd., Veradermics, Inc., Graceway Pharmaceuticals, LLC, MEDA Pharma, LEO Pharma, and others
Key Common Warts Therapies: CANDIN, VP-102, FIT039, A-101, KNP2002, 10% EISO, CLS006, VDMN-21, Resiquimod, Imiquimod, Picato, and others
Common Warts Therapeutic Assessment: Common Warts current marketed and Common Warts emerging therapies
Common Warts Market Dynamics: Common Warts market drivers and Common Warts market barriers

Request for Sample PDF Report for Common Warts Pipeline Assessment and clinical trials

Table of Contents

1. Common Warts Report Introduction

2. Common Warts Executive Summary

3. Common Warts Overview

4. Common Warts- Analytical Perspective In-depth Commercial Assessment

5. Common Warts Pipeline Therapeutics

6. Common Warts Late Stage Products (Phase II/III)

7. Common Warts Mid Stage Products (Phase II)

8. Common Warts Early Stage Products (Phase I)

9. Common Warts Preclinical Stage Products

10. Common Warts Therapeutics Assessment

11. Common Warts Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Common Warts Key Companies

14. Common Warts Key Products

15. Common Warts Unmet Needs

16 . Common Warts Market Drivers and Barriers

17. Common Warts Future Perspectives and Conclusion

18. Common Warts Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Common Warts Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Verrica Pharma, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics, KinoPharma Inc

Custom Ice Packs: From Cold Therapy to Marketing and Promotional Giveaways, Gelpax.com Revolutionizes the North American Market

Gelpax.com launches custom ice packs with durable, full-color branding and promotional-ready designs, offering bulk orders for North American businesses.

Gelpax, a premium manufacturer based in the North American market, is transforming the industry with its high-quality, custom ice packs, providing businesses and healthcare providers with options to enhance brand alignment and exploit branding opportunities in the consumer markets. Offering custom ice packs for every need, the company provides full-color branding to complement performance with visual appeal.

An excellent medium for branding, customization is what sets Gelpax products apart. Unlike generic cold packs, customers can choose from various gel colors, making these customized ice packs ideal for corporate giveaways, events, and retail promotions. Every Gelpax product can be imprinted with logos, contact information, and promotional messages in full color, making the print pop against the colored background.

“GelPax.com is a premier manufacturer of high-quality, custom gel ice packs to meet the diverse needs of businesses, healthcare providers, and individuals. From effective therapy gel packs and logo ice packs for brand promotion to bulk ice packs for large-scale needs, our customizable ice packs make perfect promotional giveaways. We brand all our products in full color with a choice of gel color,” said Gelpax co-founder Aston Scott.

Gelpax is redefining what customized ice packs can achieve with unmatched customization options for businesses seeking high-quality, branded cold therapy solutions. It offers a versatile range of cold therapy products, including facial ice packs for post-treatment recovery and skincare routines.

Perfect for corporate events, healthcare promotions, or as part of a wellness program, each product is crafted with medical-grade materials, ensuring safety and durability. Ideal as promotional ice packs, these products offer practical value and serve as a powerful marketing tool. Gelpax produces and ships all custom orders within 10 business days or less.

For companies seeking bulk ice packs, Gelpax offers scalable solutions without compromising quality. From sports teams requiring recovery aids to food delivery services needing temperature control, the company’s customized ice packs cater to diverse industries. The durable, leak-proof design ensures longevity, making them a cost-effective choice for large-scale distribution.

For more information, visit https://gelpax.com/

At Gelpax, consumer and environmental safety are paramount. FDA-registered and hand-made in North America, the colored gel used in its product range is the same material used in agriculture to help soil retain water.

Among its most popular products, the 4″ Small Round Ice Pack is the ultimate Hot/Cold Gel Pack designed for versatility and effectiveness. Enclosed in high-strength nylon-poly film for maximum durability, they can be used hundreds of times.

These round ice packs are preferred in medispas, dental clinics, and plastic surgery practices across North America. Perfectly shaped to contour any body part, they offer targeted natural pain relief where needed most, delivering soothing hot or cold therapy while meeting the highest quality standards for health and safety. Ideal for spas, dermatologists, and aesthetic clinics, these promotional ice packs make effective marketing tools while delivering therapeutic benefits.

The rise of branded merchandise has increased demand for promotional ice packs that combine utility with marketing impact. Gelpax’s ability to produce eye-catching, functional products positions it as a leader in the space. By prioritizing aesthetics and performance, the company meets the needs of clients looking to enhance brand visibility while providing practical cold therapy solutions.

Gelpax continues to innovate, expanding its product line to meet emerging trends. As more industries recognize the value of functional promotional products, Gelpax is poised to remain a key player in the custom ice packs industry, catering to the booming skincare and wellness markets, offering targeted relief with a sleek, branded design.

About the Company:

Gelpax.com is a leading manufacturer of custom ice packs, specializing in bulk and promotional ice packs for the North American market. The company stands out by offering full-color branding on durable, medical-grade gel packs in various gel colors. From facial ice packs for skincare clinics to branded cold therapy solutions for corporate clients, Gelpax combines functionality with marketing appeal. Designed for businesses, healthcare providers, and event organizers, these customized ice packs are leak-proof, reusable, and ideal for branding.

Media Contact
Company Name: Gelpax
Contact Person: Aston Scott
Email: Send Email
Country: United States
Website: https://gelpax.com/

More High-Performing Leaders Turn to Breathwork to Address Burnout, Says Emotional Resilience Expert Sam Kabert

Silicon Valley, CA – May 21, 2025 – A growing number of high-performing professionals are adopting science-backed tools to better manage burnout and regulate emotional states, according to Sam Kabert, a Breathwork & Emotional Resilience Expert. This shift marks a significant departure from how executives and entrepreneurs approach stress, performance, and long-term well-being.

Sam Kabert, Breathwork & Emotional Resilience Expert

“We’re seeing a mindset shift. Today’s leaders want tools that go beyond productivity hacks – tools that help them reconnect with themselves, make better decisions, and show up with more intention,” said Kabert. “You can’t mindset your way out of a nervous system problem, which is why we focus on physiological tools that address stress and regulation at the root.”

Kabert is among a new generation of coaches and facilitators leveraging science-backed practices like breathwork, subconscious reprogramming, and Mental Emotional Release (MER) to help high-performing professionals shift from coping mechanisms to transformational self-regulation.

This comes amid increasing attention to the connection between the nervous system and performance. According to the American Institute of Stress, 52% of men and 42% of women report that stress negatively impacts their ability to stay focused the following day.

Kabert’s 6-step B.R.E.A.T.H. Method is part of this broader movement toward physiological self-mastery. It combines intentional breathing, somatic awareness, and subconscious release techniques to help professionals quickly shift from reactive to regulated states in as little as two minutes. This rapid reset is grounded in the work of neuroanatomist Dr. Jill Bolte Taylor, who discovered that the body has a 90-second physiological response to emotion. If allowed to move through the emotion, it naturally releases. Rather than pushing through stress with willpower, the method teaches users to pause, reset, and re-engage from a place of clarity and calm.

The 6-step B.R.E.A.T.H. Method follows this process:

Breathe to Slow Down
Relax to Feel
Energy to Reveal
Accept to Surrender
Transform into Empowering Beliefs
Habits to Integrate

Each step builds upon the previous, to guide users from overwhelm to clarity in a simple, repeatable format that doesn’t require them to step away from their responsibilities.

While his framework has been active for some time, Kabert says interest has grown in the past year as companies seek more integrated approaches to leadership development and employee wellbeing. It is resonating strongly in today’s evolving work culture, where traditional “hustle” narratives are being replaced with a deeper emphasis on mental clarity, emotional intelligence, and internal alignment.

For additional information about Sam Kabert’s approach to burnout recovery and emotional resilience, please visit https://samkabert.com/.

Media Contact
Company Name: Sam Kabert, Breathwork & Emotional Resilience Expert
Contact Person: Sam Kabert
Email: Send Email
Phone: (408) 550-4859
Country: United States
Website: https://samkabert.com/

Expert Garage Door Repair and Installations: Strongdoor Garage Of Boulder Expands Its Presence in Colorado with New Boulder Location

Strongdoor Garage Of Boulder opens in Boulder, providing fast, reliable garage door repair, installation, maintenance, and 24/7 emergency services with transparent pricing.

Strongdoor Garage Of Boulder, a trusted name in residential and commercial garage door repair and installation services, has opened a new location in Boulder, Colorado. With years of industry experience, the company provides reliable, efficient, and high-quality solutions for homeowners and businesses in the area with no extra charge for evening or weekend visits.

A community-focused business, Strongdoor Garage of Boulder stands out for its commitment to customer satisfaction, rapid response times, and skilled technicians. The Boulder location will offer the same expertise and professionalism that has made the company a preferred choice in neighboring communities.

From broken springs to malfunctioning garage door openers, Strongdoor Garage Of Boulder handles all aspects of garage door repair. The company’s technicians are trained to diagnose and fix issues quickly, minimizing customer downtime. Common services include spring replacement, track realignment, sensor adjustments, and opener troubleshooting.

“When it comes to garage door problems, time is of the essence. That’s why we provide same-day service for all needs, from emergency garage door repairs to garage door installations, including evenings and weekends. We do not believe in taking advantage of a customer just because they need an evening or weekend appointment,” said company president Luis Chuchon.

When old garage doors require replacement, Strongdoor Garage Of Boulder provides top-tier garage door installation services with a wide selection of materials, styles, and insulation options to match any architectural preference or budget. Fully certified for safety and quality assurance, licensed and insured technicians ensure precise measurements, proper alignment, and seamless integration with existing systems.

Energy-efficient and noise-reducing options are also available for homeowners seeking modern, high-performance solutions. Strongdoor Garage of Boulder offers transparent pricing with no hidden fees, helping customers make informed decisions before work begins.

For more information, visit https://strongdoorgarage.com/garage-door-services-boulder-co/

Nestled against the foothills of the Rocky Mountains at an elevation of over 5,400 feet, Boulder experiences fluctuating weather, requiring durable, well-insulated garage door systems to deal with extreme snow during winters and blazing summers. The city receives over 300 days of sunshine annually, causing significant temperature swings that can affect garage door components.

Residents across Colorado trust Strongdoor Garage Of Boulder for its professional installation services and high-quality materials, such as the state-of-the-art garage door opener from Liftmaster Of Craftsman, matching the high standards customers expect for quality, sustainability, and design. Specializing in spring replacements, opener fixes, track adjustments, and full-door installations, the company ensures safety, durability, and energy efficiency.

Understanding the importance of having a functioning garage door, Strongdoor Garage Of Boulder is on hand to resolve the issue when a system breakdown occurs, providing a reliable and fast 24/7 emergency service to fix garage doors on the same day.

“A faulty garage door isn’t just an inconvenience, but a potential safety hazard. To ensure security and functionality, we prioritize fast, durable repairs with its 24/7 emergency services. Breakdowns happen suddenly when people least expect it. They don’t wait for business hours, and neither does Strongdoor Garage Of Boulder,” added Chuchon.

With its new Boulder location, Strongdoor Garage Of Boulder reinforces its mission to deliver dependable and affordable garage door solutions to residents in the area. A trusted provider of premier residential and commercial garage door services, the company specializes in repair, installation, and maintenance services, leveraging its excellent reputation for customer care and technical excellence to continue its expansion across Colorado.

About the Company:

Strongdoor Garage Of Boulder is a trusted name in garage door repair, installation, and maintenance, offering reliable, fast, and affordable solutions for homes and businesses. Locally owned and operated, the new Boulder location is backed by a team of licensed technicians and continues the company’s commitment to quality workmanship and reliable 24/7 emergency service. With its community-first approach, Strongdoor Garage Of Boulder is the go-to choice for dependable garage door solutions.

Media Contact
Company Name: Strongdoor Garage Of Boulder
Contact Person: Luis Chuchon
Email: Send Email
Phone: 720-527-0080
Address:3065 Center Green Dr Unit 250
City: Boulder
State: CO 80301
Country: United States
Website: https://strongdoorgarage.com/garage-door-services-boulder-co/

Cold Agglutinin Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Apellis Pharma, Novartis, Incyte, Sanofi, Alexion Pharma

The Key Cold Agglutinin Disease Companies in the market include – Apellis Pharmaceuticals, Novartis, Incyte corporation, Sanofi, Alexion Pharmaceuticals, Novartis, and others.

DelveInsight’s “Cold Agglutinin Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Cold Agglutinin Disease, historical and forecasted epidemiology as well as the Cold Agglutinin Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Cold Agglutinin Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cold Agglutinin Disease Market Forecast

Some of the key facts of the Cold Agglutinin Disease Market Report:

The Cold Agglutinin Disease market size was valued ~USD 190 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In May 2025, Riliprubart (SAR445088), an experimental therapy being explored as a potential follow-up to Enjaymo (sutimlimab-jome) for treating cold agglutinin disease (CAD), may maintain effective drug levels with a fixed dose administered once every three months. This conclusion comes from a study that applied modeling techniques to existing clinical trial data to determine an optimal dosing schedule. The proposed regimen was subsequently validated in a Phase 1 clinical trial involving nine CAD patients.
In November 2024, Annexon Biosciences announced that results from its ongoing proof-of-concept clinical trial evaluating ANX1502, a novel treatment for cold agglutinin disease (CAD), are now anticipated in early 2025. The study is assessing a newly developed tablet formulation of the oral therapy in individuals diagnosed with CAD.
In 2023, Germany held the largest share of the CAD market within the EU4 and the UK, totaling approximately USD 18 million.
In January 2024, In a Phase 1 clinical trial, Annexon Biosciences’ experimental oral therapy, ANX1502, designed for autoimmune conditions like cold agglutinin disease (CAD), achieved the targeted blood levels when administered twice daily to healthy volunteers. ANX1502, delivered as a liquid suspension, was well-received with no significant adverse effects reported. The pharmacokinetics of ANX1502, detailing its distribution, metabolism, and elimination from the body, also indicated the feasibility of implementing a twice-daily dosing regimen for future proof-of-concept studies.
In 2023, there were approximately 5,500 prevalent cases of CAD in the United States.
In 2023, about 90% of CAD cases in the US were identified as type-specific primary cases, with the remaining 10% classified as secondary CAD.
Within the EU4 and the UK, Germany had the highest number of prevalent CAD cases.
In 2023, there were around 1,800 cases of CAD in males and approximately 2,660 cases in females in the US.
Key Cold Agglutinin Disease Companies: Apellis Pharmaceuticals, Novartis, Incyte corporation, Sanofi, Alexion Pharmaceuticals, Novartis, and others
Key Cold Agglutinin Disease Therapies: Pegcetacoplan, Iptacopan, Parsaclisib, SAR445088, Eculizumab, sutimlimab (BIVV009, Iptacopan, and others
The Cold Agglutinin Disease epidemiology based on gender analyzed that Cold Agglutinin Disease frequency is usually more in females than in males
The Cold Agglutinin Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cold Agglutinin Disease pipeline products will significantly revolutionize the Cold Agglutinin Disease market dynamics.

Cold Agglutinin Disease Overview

Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia characterized by the presence of cold-reacting autoantibodies, known as cold agglutinins, in the blood. These autoantibodies target and bind to red blood cells at temperatures lower than normal body temperature, leading to their premature destruction (hemolysis) when exposed to cold environments, such as cold weather or refrigeration.

Get a Free sample for the Cold Agglutinin Disease Market Report:

https://www.delveinsight.com/report-store/cold-agglutinin-disease-cad-market

Cold Agglutinin Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Cold Agglutinin Disease Epidemiology Segmentation:

The Cold Agglutinin Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Cold Agglutinin Disease
Prevalent Cases of Cold Agglutinin Disease by severity
Gender-specific Prevalence of Cold Agglutinin Disease
Diagnosed Cases of Episodic and Chronic Cold Agglutinin Disease

Download the report to understand which factors are driving Cold Agglutinin Disease epidemiology trends @ Cold Agglutinin Disease Epidemiology Forecast

Cold Agglutinin Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cold Agglutinin Disease market or expected to get launched during the study period. The analysis covers Cold Agglutinin Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cold Agglutinin Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cold Agglutinin Disease Therapies and Key Companies

Pegcetacoplan: Apellis Pharmaceuticals
Iptacopan: Novartis
Parsaclisib: Incyte corporation
SAR445088: Sanofi
Eculizumab: Alexion Pharmaceuticals
sutimlimab (BIVV009): Sanofi
Iptacopan: Novartis

Discover more about therapies set to grab major Cold Agglutinin Disease market share @ Cold Agglutinin Disease Treatment Market

Cold Agglutinin Disease Market Strengths

Several organizations and companies like Cold agglutinin disease foundation and Sanofi Genzyme are raising awareness about the disease which can lead to increased patient pool.

Cold Agglutinin Disease Market Opportunities

Mild anemic patients because of CAD don’t have such a pharmaceutical treatment option, so there is an unsaid need for the drugs in mild anemic patients.

Scope of the Cold Agglutinin Disease Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Cold Agglutinin Disease Companies: Apellis Pharmaceuticals, Novartis, Incyte corporation, Sanofi, Alexion Pharmaceuticals, Novartis, and others
Key Cold Agglutinin Disease Therapies: Pegcetacoplan, Iptacopan, Parsaclisib, SAR445088, Eculizumab, sutimlimab (BIVV009, Iptacopan, and others
Cold Agglutinin Disease Therapeutic Assessment: Cold Agglutinin Disease current marketed and Cold Agglutinin Disease emerging therapies
Cold Agglutinin Disease Market Dynamics: Cold Agglutinin Disease market drivers and Cold Agglutinin Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Cold Agglutinin Disease Unmet Needs, KOL’s views, Analyst’s views, Cold Agglutinin Disease Market Access and Reimbursement

To know more about Cold Agglutinin Disease companies working in the treatment market, visit @ Cold Agglutinin Disease Clinical Trials and Therapeutic Assessment

Table of Contents

1. Cold Agglutinin Disease Market Report Introduction

2. Executive Summary for Cold Agglutinin Disease

3. SWOT analysis of Cold Agglutinin Disease

4. Cold Agglutinin Disease Patient Share (%) Overview at a Glance

5. Cold Agglutinin Disease Market Overview at a Glance

6. Cold Agglutinin Disease Disease Background and Overview

7. Cold Agglutinin Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Cold Agglutinin Disease

9. Cold Agglutinin Disease Current Treatment and Medical Practices

10. Cold Agglutinin Disease Unmet Needs

11. Cold Agglutinin Disease Emerging Therapies

12. Cold Agglutinin Disease Market Outlook

13. Country-Wise Cold Agglutinin Disease Market Analysis (2020–2034)

14. Cold Agglutinin Disease Market Access and Reimbursement of Therapies

15. Cold Agglutinin Disease Market Drivers

16. Cold Agglutinin Disease Market Barriers

17. Cold Agglutinin Disease Appendix

18. Cold Agglutinin Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cold Agglutinin Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Apellis Pharma, Novartis, Incyte, Sanofi, Alexion Pharma